Abstract
Background and aims: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer. Although two immune checkpoint inhibitors are approved for the treatment of advanced stage MCC, less than half of patients achieve durable benefit. Therefore, we sought to identify new and effective treatments for MCC. Methods: To identify novel treatments for MCC, we performed high-throughput screening of ∼4,000 small molecules on MCC cell lines. Additionally, we conducted mechanistic studies using molecular profiling, cell viability assays, and antioxidant assays.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.